Emerging therapies for the treatment of relapsed or refractory multiple myeloma

被引：57

作者：

Dimopoulos, Meletios A. ^{[1
]}

San-Miguel, Jesus F. ^{[2
]}

Anderson, Kenneth C. ^{[3
]}

机构：

[1] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 11528, Greece

[2] Univ Hosp Salamanca, Salamanca, Spain

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2011年 / 86卷 / 01期

关键词：

multiple myeloma; immunomodulatory drug; proteasome inhibitor; Akt inhibitor; histone deacetylase inhibitor; LENALIDOMIDE PLUS DEXAMETHASONE; PEGYLATED LIPOSOMAL DOXORUBICIN; SUBEROYLANILIDE HYDROXAMIC ACID; STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; PHASE-I; VAD CHEMOTHERAPY; DEACETYLASE INHIBITOR; BORTEZOMIB; THALIDOMIDE;

D O I：

10.1111/j.1600-0609.2010.01542.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Encouraging progress has been made in the treatment of patients with relapsed/refractory multiple myeloma (MM). The rapidly evolving understanding of key pathways responsible for tumor growth and survival has led to the development of novel agents (including immunomodulatory drugs, proteasome inhibitors, histone deacetylase inhibitors, and other targeted agents) with the potential to provide significant improvements in response and survival, and influence treatment guidelines. This review summarizes recent advances in understanding of the biology of relapsed/refractory MM and clinical trials with novel targeted agents that are currently under investigation for patients with this disease.

引用

页码：1 / 15

页数：15

共 118 条

[1] Dacetuzurmab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study [J].

Agura, Edward ;

Niesvizky, Ruben ;

Matous, Jeffrey ;

Munshi, Nikhil ;

Hussein, Mohamad ;

Parameswaran, Ramakrishnan V. ;

Tarantolo, Stefano ;

Whiting, Nancy C. ;

Drachman, Jonathan G. ;

Zonder, Jeffrey A. .

BLOOD, 2009, 114 (22) :1120-1121

[2] Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1 [J].

Anderson, G ;

Gries, M ;

Kurihara, N ;

Honjo, T ;

Anderson, J ;

Donnenberg, V ;

Donnenberg, A ;

Ghobrial, I ;

Mapara, MY ;

Stirling, D ;

Roodman, D ;

Lentzsch, S .

BLOOD, 2006, 107 (08) :3098-3105

[3] VAD CHEMOTHERAPY AS REMISSION INDUCTION FOR MULTIPLE-MYELOMA [J].

ANDERSON, H ;

SCARFFE, JH ;

RANSON, M ;

YOUNG, R ;

WIERINGA, GS ;

MORGENSTERN, GR ;

FITZSIMMONS, L ;

RYDER, D .

BRITISH JOURNAL OF CANCER, 1995, 71 (02) :326-330

[4] Clinically relevant end points and new drug approvals for myeloma [J].

Anderson, K. C. ;

Kyle, R. A. ;

Rajkumar, S. V. ;

Stewart, A. K. ;

Weber, D. ;

Richardson, P. .

LEUKEMIA, 2008, 22 (02) :231-239

[5]

Anderson KC, 2009, J CLIN ONCOL, V27

[6]

[Anonymous], 2009, CLIN PRACT GUID ONC

[7]

[Anonymous], J CLIN ONCOL ASCO S

[8] Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].

Avet-Loiseau, Herve ;

Attal, Michel ;

Moreau, Philippe ;

Charbonnel, Catherine ;

Garban, Frederic ;

Hulin, Cyrille ;

Leyvraz, Serge ;

Michallet, Mauricette ;

Yakoub-Agha, Ibrahim ;

Garderet, Laurent ;

Marit, Gerald ;

Michaux, Lucienne ;

Voillat, Laurent ;

Renaud, Marc ;

Grosbois, Bernard ;

Guillerm, Gaelle ;

Benboubker, Lotfi ;

Monconduit, Mathieu ;

Thieblemont, Catherine ;

Casassus, Philippe ;

Caillot, Denis ;

Stoppa, Anne-Marie ;

Sotto, Jean-Jacques ;

Wetterwald, Marc ;

Dumontet, Charles ;

Fuzibet, Jean-Gabriel ;

Azais, Isabelle ;

Dorvaux, Veronique ;

Zandecki, Marc ;

Bataille, Regis ;

Minvielle, Stephane ;

Harousseau, Jean-Luc ;

Facon, Thierry ;

Mathiot, Claire .

BLOOD, 2007, 109 (08) :3489-3495

[9] Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma [J].

Badros, Ashraf ;

Burger, Angelika M. ;

Philip, Sunita ;

Niesvizky, Ruben ;

Kolla, Sarah S. ;

Goloubeva, Olga ;

Harris, Carolynn ;

Zwiebel, James ;

Wright, John J. ;

Espinoza-Delgado, Igor ;

Baer, Maria R. ;

Holleran, Julianne L. ;

Egorin, Merrill J. ;

Grant, Steven .

CLINICAL CANCER RESEARCH, 2009, 15 (16) :5250-5257

[10]

Badros AZ, 2009, BLOOD, V114, P3877

← 1 2 3 4 5 6 7 8 9 10 →